Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-lβ-induced β-cell impairment and activation of islet cell apoptosis in vitro

Diabetes

Volumn 48, Issue 9, 1999, Pages 1730-1736

  Giannoukakis, Nick ^a   Rudert, William A ^a   Ghivizzani, Steve C ^a   Gambotto, Andrea ^a   Ricordi, Camillo ^b   Trucco, Massimo ^a   Robbins, Paul D ^a,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; FAS ANTIGEN; GLUCOSE; GREEN FLUORESCENT PROTEIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NITRIC OXIDE;

ADENOVIRUS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MACROPHAGE; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ADENOVIRIDAE; APOPTOSIS; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GLUCOSE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; NITRIC OXIDE; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; TRANSPLANTATION, HOMOLOGOUS; VIRUS REPLICATION;

EID: 0032830997     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.9.1730     Document Type: Article

References (52)

1. Bach JF: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15:516-542, 1994
2. Tisch R, McDevitt H: Insulin-dependent diabetes mellitus. Cell 85:291-297, 1996
3. Brennan FM, Feldmann M: Cytokines in autoimmunity. Curr Opin Immunol 4:754-759, 1992
4. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995
5. Reddy S, Liu W, Elliott RB: Distribution of pancreatic macrophages preceding and during early insulitis in young NOD mice. Pancreas 8:602-608, 1993
6. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA: Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 160:2684-2691, 1998
7. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA: IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 102:516-526, 1998
8. McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA: Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211:24-32, 1996
9. Corbett JA, Wang JL, Misko TP, Zhao W, Hickey WF, McDaniel ML: Nitric oxide mediates IL-1 beta-induced islet dysfunction and destruction: prevention by dexamethasone. Autoimmunity 15:145-153, 1993
10. Corbett JA, Wang JL, Sweetland MA, Lancaster JR Jr, McDaniel ML: Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans: evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 90:2384-2391, 1992
11. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K: Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 39: 1306-1312, 1996
12. Stassi G, Maria RD, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M: Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 186:1193-1200, 1997
13. Corbett JA, Wang JL, Hughes JH, Wolf BA, Sweetland MA, Lancaster JR, Jr., McDaniel ML: Nitric oxide and cyclic GMP formation induced by interleukin 1 beta in islets of Langerhans: evidence for an effector role of nitric oxide in islet dysfunction. Biochem J 287:229-235, 1992
14. Corbett JA, McDaniel ML: Reversibility of interleukin-1 beta-induced islet destruction and dysfunction by the inhibition of nitric oxide synthase. Biochem J 299:719-724, 1994
15. Bolaffi JL, Rodd GG, Wang J, Grodsky GM: Interrelationship of changes in islet nicotine adeninedinucleotide, insulin secretion, and cell viability induced by interleukin-1 beta. Endocrinology 134:537-542, 1994
16. Lacy PE, Finke EH: Activation of intraislet lymphoid cells causes destruction of islet cells. Am J Pathol 138:1183-1190, 1991
17. Lacy PE: The intraislet macrophage and type I diabetes. Mt Sinai J Med 61: 170-174, 1994
18. Scarim AL, Arnush M, Hill JR, Marshall CA, Baldwin A, McDaniel ML, Corbett JA: Evidence for the presence of type I IL-1 receptors on beta-cells of islets of Langerhans. Biochim Biophys Acta 1361:313-320, 1997
19. Cailleau C, Diu-Hercend A, Ruuth E, Westwood R, Carnaud C: Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46:937-940, 1997
20. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP: Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266:10331-10336, 1991
21. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA: Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79:2364-2369, 1992
22. Symons JA, Young PR, Duff GW: Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 92:1714-1718, 1995
23. Thompson RC, Dripps DJ, Eisenberg SP: IL-1ra: properties and uses of an interleukin-1 receptor antagonist. Agents Actions Suppl 35:41-49, 1991
24. Dinarello CA: Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int Suppl 38:S68-S77, 1992
25. Dinarello CA: Anti-cytokine strategies. Eur Cytokine Network 3:7-17, 1992
26. Dripps DJ, Verderber E, Ng RK, Thompson RC, Eisenberg SP: Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J Biol Chem 266:20311-20315, 1991
27. Sandberg JO, Eizirik DL, Sandler S: IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 108:314-317, 1997
28. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vectors through Cre-Iox recombination. J Virol 71:1842-1849, 1997
29. Mittereder N, March KL, Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509, 1996
30. Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C: Improved human islet isolation using anew enzyme blend, liberase. Diabetes 46:1120-1123, 1997
31. Weber M, Deng S, Kucher T, Snaked A, Ketchum RJ, Brayman KL: Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. J Surg Res 69:23-32, 1997
32. Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764, 1994
33. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair a fundamental principle of apoptotic death. J Exp Med 183:1957-1964, 1996
34. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347, 1994
35. Heitmeier MR, Scarim AL, Corbett JA: Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J Biol Chem 272:13697-13704, 1997
36. Kolb-Bachofen V, Schraermeyer U, Hoppe T, Hanenberg H, Kolb H: Diabetes manifestation in BB rats is preceded by pan-pancreatic presence of activated inflammatory macrophages. Pancreas 7:578-584, 1992
37. Murphy C, Newsholme P: The enemy within: the role played by immunostimulated macrophages in the pathogenesis of insulin dependent diabetes mellitus. Biochem Soc Trans 25:368S, 1997
38. Hanenberg H, Kolb-Bachofen V, Kantwerk-Funke G, Kolb H: Macrophage infiltration precedes and is a prerequisite for lymphocytic insulitis in pancreatic islets of pre-diabetic BB rats. Diabetologia 32:126-134, 1989
39. Dayer-Metroz MD, Wollheim CB, Seckinger P, Dayer JM: A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J Autoimmun 2:163-171, 1989
40. Nicoletti F, Di Marco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, Meroni P: Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 24:1843-1847, 1994
41. Andreoletti L, Hober D, Hober-Vandenberghe C, Belaich S, Vantyghem MC, Lefebvre J, Wattre P: Detection of coxsackie B virus RNA sequences in whole blood samples from adult patients at the onset of type I diabetes mellitus. J Med Virol 52:121-127, 1997
42. Lonnrot M, Hyoty H, Knip M, Roivainen M, Kulmala P, Leinikki P, Akerblom HK: Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackievirus B4: Childhood Diabetes in Finland Study Group. Clin Exp Immunol 104:398-405, 1996
43. Vreugdenhil GR, Geluk A, Ottenhoff TH, Melchers WJ, Roep BO, Galama JM: Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. Diabetologia 41:40-46, 1998
44. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N: Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 4:781-785, 1998
45. Benoist C, Mathis D: Autoimmunity: the pathogen connection. Nature 394: 227-228, 1998
46. Janson RW, Hance KR, Arend WP: Production of IL-1 receptor antagonist by human in vitro-derived macrophages: effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol 147:4218-4223, 1991
47. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: the IL-1Ra Arthritis Study Group. Arthritis Rheum 39:1092-1101, 1996
48. Kreil TR, Eibl MM: Viral infection of macrophages profoundly alters requirements for induction of nitric oxide synthesis. Virology 212:174-178, 1995
49. Mihm S, Fayyazi A, Ramadori G: Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology 26:451-458, 1997
50. Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A: Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 97:1837-1843, 1996
51. Haddad IY, Sorscher EJ, Garver RI Jr, Hong J, Tzeng E, Matalon S: Modulation of adenovirus-mediated gene transfer by nitric oxide. Am J Respir Cell Mol Biol 16:501-509, 1997
52. Beckman JS, Crapo JD: The role of nitric oxide in limiting gene transfer parallels to viral host defenses. Am J Respir Cell Mol Biol 16:495-496, 1997